{
  "docId": "019de074-0bfb-75bc-a2eb-54d60d88aadd",
  "docSlug": "2fd96f096e3a949c3b11bf5955245231",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 27 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 27,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-0bfb-75bc-a2eb-54d60d88aadd/6",
  "deckHref": "/decks/019de074-0bfb-75bc-a2eb-54d60d88aadd",
  "deckJsonHref": "/decks/019de074-0bfb-75bc-a2eb-54d60d88aadd.json",
  "deckAnchorHref": "/decks/019de074-0bfb-75bc-a2eb-54d60d88aadd#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.17,
        "w": 0.17,
        "x": 0.43,
        "y": 0.57
      },
      "kind": "callout",
      "text": "Historical success rates for antibodies are significantly higher than small molecules",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "050b99d9-5b37-4692-ab00-dd9a7406edb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.63,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Acceleration of Regulatory Approvals (FDA and EMA)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ccf6a34-98d9-4ccc-95d5-e8b686944dfb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "list",
      "text": "$236B in antibody sales by 2025 (up from ~$212B in 2021)\n49 blockbuster antibodies in 2021 (up from 41 in 2020)\n5 best-selling antibodies had ~$66B of sales in 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7e031f5-43da-4028-891d-adab90c2bb92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Sources: 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics (La Merie Publishing). Tables of approved mAbs and antibodies in review available at https://www.antibodysociety.org/resources/approved-antibodies/ (1) Defined as composite success rate of clinical development from Phase I trials to Approval, data from 2011-2020. Source: BIO | QLS Advisors | Informa Feb 2021 Report.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e9cce97-33e7-4766-b1a8-c34d52078b96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "table",
      "text": "Type of Drug | Clinical Success Rates(1)\nSmall Molecules | 7.5%\nAntibodies | 12.1%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8509ff78-fe11-4fa0-93e7-18e536ad028a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "HIGHER SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "140a2465-9a4e-4093-8891-79995d5d5db6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Antibodies and Industry Demand",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7415ee04-4e8d-414b-a524-aecc3c3130e7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 6,
      "beatId": "b97a979f-6f65-4c54-92cb-e346be1bb62b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The presentation identifies the need for effective discovery technology in the biotech industry.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 6,
      "from": 6,
      "beatId": "778d00be-2fa0-4b71-b346-adde781389b3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The presentation provides an overview of the market opportunity.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}